Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib versus placebo in advanced gastrointestinal stromal tumor after imatinib and sunitinib
NL-OMON36454Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastrointestinal stromal tumor (GIST) comparing Regorafenib plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Progression-Free Survival. Started Mar 2011; status: active, not recruiting.
02
Drugs
regorafenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON36454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36454.